Australia markets open in 8 hours 26 minutes

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6001-0.1699 (-9.60%)
As of 11:31AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 13.47M
Enterprise value 9.63M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.07
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.57

Trading information

Stock price history

Beta (5Y monthly) 0.96
52-week change 3-52.25%
S&P500 52-week change 323.57%
52-week high 35.5000
52-week low 31.0780
50-day moving average 31.7399
200-day moving average 32.9719

Share statistics

Avg vol (3-month) 315.21k
Avg vol (10-day) 328.36k
Shares outstanding 57.92M
Implied shares outstanding 65.06M
Float 89.56B
% held by insiders 117.91%
% held by institutions 11.61%
Shares short (15 Apr 2024) 4575
Short ratio (15 Apr 2024) 40.03
Short % of float (15 Apr 2024) 40.01%
Short % of shares outstanding (15 Apr 2024) 40.01%
Shares short (prior month 15 Mar 2024) 45.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 317 Aug 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-115.51%
Return on equity (ttm)-1,281.43%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -16.8M
Net income avi to common (ttm)-10.01M
Diluted EPS (ttm)-2.0400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.85M
Total cash per share (mrq)0
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.95
Book value per share (mrq)-0.04

Cash flow statement

Operating cash flow (ttm)-16.43M
Levered free cash flow (ttm)-16.74M